ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: PR Newswire
MELBOURNE, Australia, July 31, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced its Appendix 4C for the quarter ending 31 July 2019.Highlights:Cash reserves of approximately AUD $22 million Streamlined operations through workforce reduction resulting in extended financial runway; retained staff members key to core R&D Financial runway to extend through BB-301 (OPMD) targeted clinical trialJerel A. Banks, M.D. Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma, commented on today's news, "With cash reserves of $22 million, the Company's current financial position is strong. Management has taken steps to streamline operations and ensure our primary ddRNAi product candidate, BB-301, will progress to receive meaningful
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Benitec Biopharma Inc. (NASDAQ: BNTC) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $30.00 price target on the stock.MarketBeat
- Rare Diseases market is projected to grow at a CAGR of 8.8% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- Gene Therapy R&D market is projected to grow at a CAGR of 29.8% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire
BNTC
Sec Filings
- 5/29/24 - Form 424B3
- 5/29/24 - Form EFFECT
- 5/16/24 - Form S-1
- BNTC's page on the SEC website